Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.59 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.59 |
| ▸ | TK1 | P04183 | 3/20 | 0.54 |
| ▸ | TK2 | O00142 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2030383 | 1.00 | LMNA (0.59) | LMNASMN1; SMN2ALOX12ADRA1ATK1 | |
| SCHEMBL21585062 | 1.00 | LMNA (0.59) | LMNASMN1; SMN2ALOX12ADRA1ATK1 | |
| SCHEMBL18214117 | 1.00 | LMNA (0.59) | LMNASMN1; SMN2ALOX12ADRA1ATK1 | |
| SCHEMBL2611574 | 1.00 | LMNA (0.59) | LMNASMN1; SMN2ALOX12ADRA1ATK1 | |
| SCHEMBL13880679 | 1.00 | LMNA (0.59) | LMNASMN1; SMN2ALOX12ADRA1ATK1 | |
| SCHEMBL13258657 | 1.00 | LMNA (0.59) | LMNASMN1; SMN2ALOX12ADRA1ATK1 | |
| SCHEMBL2611573 | 0.93 | LMNA (0.49) | LMNASMN1; SMN2ALOX12ADRA1ATK1 | |
| SCHEMBL27102653 | 0.93 | LMNA (0.49) | LMNASMN1; SMN2ALOX12ADRA1ATK1 | |
| SCHEMBL8165992 | 0.89 | LMNA (0.55) | LMNASMN1; SMN2ALOX12ADRA1ATK1 | |
| SCHEMBL29757418 | 0.89 | TK1 (0.58) | LMNASMN1; SMN2ALOX12ADRA1ATK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11180522-B2 | Disulfide-linked reversible terminators | CENTRILLION TECHNOLOGY HOLDINGS CORPORATION (KY) | 2021-11-23 | — | — | US | disclosed |
| EP-3856753-A1 | DISULFIDE-LINKED REVERSIBLE TERMINATORS | Centrillion Technology Holdings Corporation (KY) | 2021-08-04 | — | — | EP | disclosed |
| CN-113195511-A | Disulfide-linked reversible terminators | 生捷科技控股公司 | 2021-07-30 | — | — | CN | disclosed |
| US-20200399692-A1 | MODIFIED NUCLEOTIDES | SOLEXA LIMITED (GB) | 2020-12-24 | — | — | US | disclosed |
| EP-3587433-B1 | MODIFIED NUCLEOTIDES | ILLUMINA CAMBRIDGE LTD (GB) | 2020-04-22 | — | — | EP | disclosed |
| EP-3363809-B1 | MODIFIED NUCLEOTIDES FOR POLYNUCLEOTIDE SEQUENCING | ILLUMINA CAMBRIDGE LTD (GB) | 2020-04-08 | — | — | EP | disclosed |
| WO-2020069424-A1 | DISULFIDE-LINKED REVERSIBLE TERMINATORS | CENTRILLION TECHNOLOGIES, INC. (US) | 2020-04-02 | — | — | WO | disclosed |
| EP-3091026-B1 | DISULFIDE-LINKED REVERSIBLE TERMINATORS | CENTRILLION TECH HOLDINGS CORP (KY) | 2019-02-20 | — | — | EP | disclosed |
| EP-3363809-A1 | MODIFIED NUCLEOTIDES FOR POLYNUCLEOTIDE SEQUENCING | Illumina Cambridge Limited (GB) | 2018-08-22 | — | — | EP | disclosed |
| EP-3002289-B1 | MODIFIED NUCLEOTIDES FOR POLYNUCLEOTIDE SEQUENCING | ILLUMINA CAMBRIDGE LTD (GB) | 2018-02-28 | — | — | EP | disclosed |
| US-20070166705-A1 | Modified nucleotides | ILLUMINA CAMBRIDGE LIMITED (GB) | 2007-07-19 | — | — | US | disclosed |
| EP-1530578-A2 | MODIFIED NUCLEOTIDES FOR POLYNUCLEOTIDE SEQUENCING | Solexa Limited (GB) | 2005-05-18 | — | — | EP | disclosed |
| WO-2004018497-A2 | MODIFIED NUCLEOTIDES FOR POLYNUCLEOTIDE SEQUENCING | SOLEXA LIMITED (GB) | 2004-03-04 | — | — | WO | disclosed |
| US-6627456-B1 | Incorporating into the oligonucleotide analogs that are the components of a library to which in vitro selection methods functionalized standard and non-standard nucleotides, and incorporating functionalized cofactors into the experiment | BENNER, STEVEN | 2003-09-30 | — | — | US | disclosed |
| US-6031086-A | HAVING DIMINISHED CHARGE BUT UNDIMINISHED ABILITY TO COMPLEX WITH NATURAL DNA AT LOW IONIC STRENGTHS; PREPARED BY REPLACING NATURAL NUCLEOTIDES WITH UNNATURAL ZWITTERIONIC NUCLEOTIDES; MEMBRANE PERMEABLE AND NUCLEASE RESISTANT | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2000-02-29 | — | — | US | disclosed |
| US-5965364-A | Method for selecting functional deoxyribonucleotide derivatives | BENNER, STEVEN | 1999-10-12 | — | — | US | disclosed |
| US-5596091-A | DNA AND RNA FOR GENE EXPRESSION FOR DIAGNOSIS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1997-01-21 | — | — | US | disclosed |
| EP-0251786-B1 | Alkynylamino-nucleotides | DU PONT (US) | 1994-11-30 | — | — | EP | disclosed |
| US-5151507-A | Alkynylamino-nucleotides | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-09-29 | — | — | US | disclosed |
| US-5047519-A | Alkynylamino-nucleotides | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1991-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11180522-B2 | Disulfide-linked reversible terminators | RNGTT, NSUN3, NSUN2 | LMNA 413/4885SMN1; SMN2 638/4885ALOX12 2737/4885 |
| US-20200399692-A1 | MODIFIED NUCLEOTIDES | ADAR, NT5C2, NSUN2 | LMNA 639/4885SMN1; SMN2 2619/4885ALOX12 2618/4885 |
| US-20070166705-A1 | Modified nucleotides | NT5C2, ADAR, DUT | LMNA 650/4885SMN1; SMN2 2713/4885ALOX12 2455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.